Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K31/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/107182A COMPOSITION OF FENTANYL AND FATTY ACIDS, AND A METHOD OF PREPARATION THEREOF
WO 27.05.2022
Int.Class A61K 9/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
08Solutions
Appl.No PCT/JO2020/050011 Applicant UNIVERSITY OF PETRA Inventor ALAKAYLEH, Faisal Tawfiq
The present disclosure provides a pharmaceutical composition comprising Fentanyl and one or more fatty acids with eutectic mixtures capabilities, for use as an analgesic, and a method of preparation thereof.
2.WO/2022/105877PHARMACEUTICAL COMPOSITION AND PREPARATION COMPRISING BILOBALIDE COMPONENT AND USE THEREOF
WO 27.05.2022
Int.Class A61K 31/365
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
Appl.No PCT/CN2021/131779 Applicant CHENGDU BAIYU PHARMACEUTICAL CO., LTD. Inventor SUN, Yi
Disclosed are a pharmaceutical composition comprising a bilobalide component and a pharmaceutically acceptable carrier or excipient, and a pharmaceutical preparation of a bilobalide component comprising a bilobalide component, a pharmaceutically acceptable carrier or excipient, and water, and the use of the pharmaceutical composition and the pharmaceutical preparation.
3.WO/2022/106657INOSITOL HEXAKISPHOSPHATE ANALOGUES FOR TREATMENT OF CALCIFICATION ASSOCIATED KIDNEY DISEASES
WO 27.05.2022
Int.Class A61K 31/7028
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
Appl.No PCT/EP2021/082374 Applicant INOSITEC AG Inventor IVARSSON, Mattias, Emanuel
The invention is related to an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.
4.WO/2022/108352PHARMACEUTICAL COMPOSITION COMPRISING FUCOIDAN ISOLATED FROM NATURAL PRODUCT
WO 27.05.2022
Int.Class A61K 31/737
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
Appl.No PCT/KR2021/016969 Applicant NANOMEDICA INC. Inventor KWAK, Jong Hwan
The present invention provides a pharmaceutical composition comprising fucoidan isolated from Ecklonia cava, Costaria costata Saunders, rhubarb, or sea mustard.
5.WO/2022/108997COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING INFLAMMATORY OR IMMUNE-MEDIATED CONDITIONS OF SURFACE TISSUES
WO 27.05.2022
Int.Class A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
Appl.No PCT/US2021/059670 Applicant LANDOS BIOPHARMA, INC. Inventor BASSAGANYA-RIERA, Josep
Compounds, compositions, and methods for treating inflammatory or immune-mediated conditions of surface tissues. The methods preferably involve topically administering to a surface tissue an amount of a compound effective to treat an inflammatory or immune-mediated condition. The compounds include lanthionine synthetase C-like 2 (LANCL2) agonists, such as piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridine-2-yl)methanone) and salts and analogs thereof. The surface tissues include the skin and the mucosa, such as the oral mucosa. The inflammatory or immune-mediated conditions include psoriasis and dermatitis (such as atopic dermatitis), among others.
6.WO/2022/109057INHIBITION OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3)
WO 27.05.2022
Int.Class A61K 31/404
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
Appl.No PCT/US2021/059771 Applicant BROWN UNIVERSITY Inventor EL-DEIRY, Wafik, S.
The invention provides small-molecule inhibition of GSK-3 to increase efficacy of ICB and improve response in patients with microsatellite stable colorectal cancer, and possibly other tumor types. These results demonstrate 9-ING-41 in combination with αPD-1/PD-L1 therapy.
7.WO/2022/109162VECTOR SYSTEM FOR DELIVERY OF MULTIPLE POLYNUCLEOTIDES AND USES THEREOF
WO 27.05.2022
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
Appl.No PCT/US2021/059931 Applicant UMOJA BIOPHARMA, INC. Inventor SCHARENBERG, Andrew
The present disclosure relates to a vector system comprising at least two polynucleotides, each polynucleotide may comprise a polynucleotide sequence encoding a polypeptide component of a macromolecular complex. Assembly of the macromolecular complex in a cell transduced with the polynucleotides may promote growth and/or survival of a cell.
8.WO/2022/109492PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS
WO 27.05.2022
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/US2021/060634 Applicant GOSSAMER BIOSERVICES, INC. Inventor MICHELS, Theodore David
Described herein are inhibitors of JAK kinases, pharmaceutical compositions comprising them, processes for preparing them and uses of such inhibitors to treat or prevent diseases, disorders and conditions associated with kinase function.
9.WO/2022/105636SPIRO COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF
WO 27.05.2022
Int.Class C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
Appl.No PCT/CN2021/129425 Applicant SHANGHAI EUREGEN BIOPHARMA CO., LTD. Inventor CHEN, Xuxing
Disclosed are a spiro compound, a pharmaceutical composition containing same, and the use thereof. The spiro compound interferes with interaction between the protein menin and MLL1, MLL2 or MLL fusion oncoproteins, and is expected to be used for a drug for the treatment of tumors, diabetes and other diseases that depend on the activity of MLL1, MLL2 or MLL fusion proteins, and/or the protein menin.
10.WO/2022/105726PRODUCTION METHOD FOR LYCOPENE-CONTAINING GRANULES WITH EFFICIENT ANTIOXIDATION EFFECT
WO 27.05.2022
Int.Class A61K 9/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
16Agglomerates; Granulates; Microbeadlets
Appl.No PCT/CN2021/130819 Applicant ZHONGKE HEALTH INDUSTRY GROUP CORP., LTD. Inventor FENG, Peng
A production method for lycopene-containing granules with an efficient antioxidation effect. The method comprises: extracting Ganoderma lucidum spore oil from Ganoderma lucidum spore powder having a broken sporoderm rate of 90%-92% by means of a CO2 supercritical extraction process to obtain degreased Ganoderma lucidum spore powder; and mixing the degreased Ganoderma lucidum spore powder and lycopene oil resin at a weight ratio of (1-2):(1-2), and performing spray granulation on same. In a granular product prepared by using the method, the effective component content is high, the lycopene content is more than 6%, and the polysaccharide content is more than 0.8%; and the product has good stability and has an efficient antioxidation effect.